Document Type
Journal Article
Department/Unit
Department of Chemistry
Title
In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma
Language
English
Abstract
We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15. mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma. © 2010 Elsevier GmbH.
Keywords
Corilagin, Hepatocellular carcinoma, Xenograft model
Publication Date
2010
Source Publication Title
Phytomedicine
Volume
18
Issue
1
Start Page
11
End Page
15
Publisher
Elsevier
DOI
10.1016/j.phymed.2010.09.001
Link to Publisher's Edition
http://dx.doi.org/10.1016/j.phymed.2010.09.001
ISSN (print)
09447113
ISSN (electronic)
1618095X
Recommended Citation
Hau, Desmond Kwok-Po, Guo-Yuan Zhu, Alexander Kai-Man Leung, Raymond Siu-Ming Wong, Gregory Yin-Ming Cheng, Paul Bo-San Lai, Sze-Wai Tong, Fung-Yi Lau, Kit-Wah Chan, Wai-Yeung Wong, Kim-Hung Lam, Chor-Hing Cheng, Filly Cheung, Chung-Hin Chui, Roberto Gambari, and David Wang-Fun Fong. "In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma." Phytomedicine 18.1 (2010): 11-15.